Table of Contents

company-logo

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics Dividend Announcement

• Entrada Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Entrada Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Entrada Therapeutics Dividend History

Entrada Therapeutics Dividend Yield

Entrada Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Entrada Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Entrada Therapeutics Financial Ratios

P/E ratio14.71
PEG ratio-0.27
P/B ratio1.91
ROE16.11%
Payout ratio0.00%
Current ratio6.59
Quick ratio6.64
Cash Ratio1.11

Entrada Therapeutics Dividend FAQ

Does Entrada Therapeutics stock pay dividends?
Entrada Therapeutics does not currently pay dividends to its shareholders.
Has Entrada Therapeutics ever paid a dividend?
No, Entrada Therapeutics has no a history of paying dividends to its shareholders. Entrada Therapeutics is not known for its dividend payments.
Why doesn't Entrada Therapeutics pay dividends?
There are several potential reasons why Entrada Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Entrada Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Entrada Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Entrada Therapeutics a dividend aristocrat?
Entrada Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Entrada Therapeutics a dividend king?
Entrada Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Entrada Therapeutics a dividend stock?
No, Entrada Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Entrada Therapeutics stocks?
To buy Entrada Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Entrada Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.